Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 5;23(1):261.
doi: 10.1186/s13063-022-06201-3.

DICE: Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian cancer resistant to standard treatment-a study protocol for a randomised trial investigating a novel therapy called TAK228

Francesca Fiorentino  1 , Jonathan Krell  2 , Consuelo Nohpal de la Rosa  2 , Lee Webber  3
Affiliations

DICE: Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian cancer resistant to standard treatment-a study protocol for a randomised trial investigating a novel therapy called TAK228

Francesca Fiorentino et al. Trials. .

Abstract

Background: The standard initial treatment for ovarian cancer is surgery and platinum-based chemotherapy and potentially maintenance therapy with avastin or inhibitors of poly-ADP ribose polymerase (PARP). While a proportion of women are cured by this approach, the vast majority will relapse and become resistant to platinum chemotherapy either initially or on subsequent treatment. There is an unmet need to improve response to treatment and quality of life in these women. TAK228 is a novel therapy that can be added to standard treatment in the participant population and the aim of the DICE trial is to assess its effectiveness. Laboratory and clinical research has shown that these ovarian cancers may respond to the molecular target of a drug such as TAK228, and there have been studies using it in other advanced solid tumours including endometrial cancer.

Methods: One hundred twenty-four eligible women will be recruited from participating research sites in the United Kingdom (UK) and Germany. Randomised participants will receive either weekly paclitaxel alone (standard treatment, n = 62) or TAK228 plus weekly paclitaxel (n = 62) until the cancer significantly worsens; there are significant adverse events or any other protocol-defined stopping criteria. Participants will be monitored for response to treatment (using radiological imaging), adverse events and quality of life during both randomised treatment and subsequent follow-up.

Discussion: The primary objective/endpoint of the study is to compare the two treatments in terms of progression-free survival, or the length of time that each participant is alive without the cancer significantly worsening according to defined assessment criteria. If the addition of TAK228 to weekly paclitaxel chemotherapy is shown to significantly improve this statistically, and adverse events and quality of life are not significantly worse than standard treatment, then TAK228 plus weekly paclitaxel could potentially be taken forward within the context of a larger phase III trial.

Trial registration: ClinicalTrials.gov NCT03648489 . Registered on 27 August 2018.

Keywords: Ovarian cancer; Platinum-resistant; TAK228; Weekly paclitaxel.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Trial scheme/flowchart
See this image and copyright information in PMC

References

    1. National Institute for Health and Care Excellence. Ovarian cancer: How common is it? https://cks.nice.org.uk/topics/ovarian-cancer/background-information/inc.... Accessed 25 Mar 2021.
    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403. doi: 10.1016/j.ejca.2012.12.027. - DOI - PubMed
    1. Cancer Research UK. Ovarian cancer statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/s.... Accessed 25 Mar 2021.
    1. Lee J-Y, Kim S, Kim YT, Lim MC, Lee B, Jung K-W, Kim JW, Park S-Y, Won Y-J. Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. BMC Cancer. 2018;18(1):601. doi: 10.1186/s12885-018-4498-z. - DOI - PMC - PubMed
    1. Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim J-W, Park S-Y, Kim B-G, Nam J-H, Fujiwara K, Walker JL. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381(20):1929–1939. doi: 10.1056/NEJMoa1902626. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data